SCHEMBL1225618

SCHEMBL1225618

CCOC(CC(=O)NNC(=O)c1c(-c2c(Cl)cccc2Cl)noc1C)OCC

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Predicted protein targets (top 13)

geneUniProtsupporting neighboursconfidence
▸ POLB P06746 1/20 1.00
▸ ALDH1A1 P00352 3/20 0.57
▸ KDM4E B2RXH2 1/20 0.57
▸ GAA P10253 1/20 0.57
▸ MAPT P10636 1/20 0.57
▸ TDP1 Q9NUW8 1/20 0.57
▸ GLA P06280 1/20 0.56
▸ PKM P14618 1/20 0.56
▸ GHSR Q92847 5/20 0.54
▸ PTGS2 P35354 3/20 0.54
▸ KMT2A Q03164 1/20 0.53
▸ TSHR P16473 1/20 0.51
▸ LMNA P02545 1/20 0.51

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7058846 0.76 TSHR (0.72) ALDH1A1KDM4EGAAMAPTTDP1
SCHEMBL1224417 0.75 ALDH1A1 (0.77) POLBALDH1A1KDM4EGAAMAPT
SCHEMBL16448979 0.75 TSHR (0.66) POLBALDH1A1GAAMAPTTDP1
SCHEMBL1224858 0.73 ALDH1A1 (1.00) ALDH1A1KDM4EGAAMAPTTDP1
SCHEMBL3106255 0.73 PTGS2 (0.67) POLBALDH1A1KDM4EGAAMAPT
SCHEMBL1225210 0.72 ALDH1A1 (0.72) POLBALDH1A1KDM4EGAAMAPT
SCHEMBL11894104 0.72 POLB (0.77) POLBALDH1A1KDM4EGAAMAPT
SCHEMBL12600509 0.72 SMN1; SMN2 (0.86) ALDH1A1KDM4EGAAMAPTTDP1
SCHEMBL3108196 0.71 POLB (0.55) POLBALDH1A1KDM4EGAAMAPT
SCHEMBL3108173 0.71 POLB (0.55) POLBALDH1A1KDM4EGAAMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20050096372-A1 Small-molecule modulators of hepatocyte growth factor/scatter factor activities PILLARISETTI SIVARAM (US) 2005-05-05 — — US claimed
US-20030216459-A1 Small-molecule modulators of hepatocyte growth factor / scatter factor activities THE FEINSTEIN INSTITUTES FOR MEDICAL RESEARCH 2003-11-20 — — US claimed
US-20030045559-A1 Small-molecule modulators of hepatocyte growth factor / scatter factor activities NORTH SHORE-LONG ISLAND JEWISH HEALTH SYSTEM 2003-03-06 — — US claimed
US-8193177-B2 Hepatocyte growth factor pathway activators in fibrotic connective tissue diseases ANGION BIOMEDICA CORP. (US) 2012-06-05 — — US disclosed
US-7879898-B1 treating a chronic obstructive pulmonary disease using modulators of HGF/SF activity; for example, 3-(5-chloro-1,3-dimethyl-1H-pyrazol-4-yl)-1-(4-chlorophenyl)prop-2-en-1-one; emphysema ANGION BIOMEDICA CORP. (US) 2011-02-01 — — US disclosed
US-20100256117-A1 HEPATOCYTE GROWTH FACTOR PATHWAY ACTIVATORS IN FIBROTIC CONNECTIVE TISSUE DISEASES ANGION BIOMEDICA CORP. 2010-10-07 — — US disclosed
WO-2009064422-A2 HEPATOCYTE GROWTH FACTOR PATHWAY ACTIVATORS IN FIBROTIC CONNECTIVE TISSUE DISEASES ANGION BIOMEDICA CORP. (US) 2009-05-22 — — WO disclosed
US-20050096372-A1 Small-molecule modulators of hepatocyte growth factor/scatter factor activities PILLARISETTI SIVARAM (US) 2005-05-05 — — US disclosed
US-6855728-B2 Small-molecule modulators of hepatocyte growth factor / scatter factor activities NORTH SHORE-LONG ISLAND JEWISH HEALTH SYSTEM (US) 2005-02-15 — — US disclosed
US-20030216459-A1 Small-molecule modulators of hepatocyte growth factor / scatter factor activities THE FEINSTEIN INSTITUTES FOR MEDICAL RESEARCH 2003-11-20 — — US disclosed
EP-1355921-A2 MODULATORS OF CELLULAR PROLIFERATION AND ANGIOGENESIS, METHODS FOR USE AND IDENTIFICATION THEREOF North Shore-Long Island Jewish Health System (US) 2003-10-29 — — EP disclosed
WO-2002002593-A2 MODULATORS OF CELLULAR PROLIFERATION AND ANGIOGENESIS, METHODS FOR USE AND IDENTIFICATION THEREOF NORTH SHORE-LONG ISLAND JEWISH HEALTH SYSTEM (US) 2002-01-10 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030045559-A1 Small-molecule modulators of hepatocyte growth factor / scatter factor activities HGF, HDGF, MET POLB 2271/4885ALDH1A1 510/4885KDM4E 4594/4885
US-20030216459-A1 Small-molecule modulators of hepatocyte growth factor / scatter factor activities HGF, HDGF, MET POLB 2271/4885ALDH1A1 510/4885KDM4E 4594/4885
US-20050096372-A1 Small-molecule modulators of hepatocyte growth factor/scatter factor activities HGF, HDGF, MET POLB 2271/4885ALDH1A1 510/4885KDM4E 4594/4885
US-20100256117-A1 HEPATOCYTE GROWTH FACTOR PATHWAY ACTIVATORS IN FIBROTIC CONNECTIVE TISSUE DISEASES HGF, HDGF, HGFAC POLB 3042/4885ALDH1A1 1992/4885KDM4E 4513/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback